United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average
| Key metrics |
|---|
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Raphael Pharmaceutical Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Actual |
|---|
| Forecast |
|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|
| ROE | 117.61% | 61.14% | 37.94% | 27.51% | 21.57% | 17.74% |
|---|---|---|---|---|---|---|
| Sector average | 20.42% | 71.17% | 5.82% | 58.79% | 17.46% | 2.74% |
| Total Assets | $53.00K | $33.00K | $33.00K | $33.00K | $33.00K | $33.00K |
| Net Income | -$1,279.00K | -$1,262.00K | -$1,262.00K | -$1,262.00K | -$1,262.00K | -$1,262.00K |